<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643367</url>
  </required_header>
  <id_info>
    <org_study_id>SSiS</org_study_id>
    <nct_id>NCT03643367</nct_id>
  </id_info>
  <brief_title>Sevoflurane Sedation in Patients With Septic Shock</brief_title>
  <acronym>SSiS</acronym>
  <official_title>Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantonsspital Münsterlingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triemli Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Waid City Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent in vivo studies from others as well as the investigators group demonstrated that
      volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials
      have convincingly shown that application of a volatile anesthetic provides protection in
      patients undergoing major surgery.

      Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most
      ICU centers use intravenously applied sedatives in these patients. In the proposed study, we
      will switch sedation from an intravenous to a volatile anesthetic for a short period of time
      to explore if sepsis markers improve within the following 120 hours upon sevoflurane
      conditioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled trial (RCT) will be conducted over a period of 48 months, to
      investigate if volatile anesthetics have a positive effect on the prognostic sepsis marker
      IL-6. All patients with septic shock are intubated, ventilated and sedated with an
      intravenous anesthetic. In this study, eligible patients diagnosed with septic shock will be
      randomized 1:1 to the 'volatile group' with interruption of the propofol infusion, followed
      by a 4-hour sedation with the volatile anesthetic sevoflurane, or a continuous intravenous
      sedation ('intravenous' =control group). In both groups, 'intravenous' and 'volatile', the
      inflammatory markers as well as clinical parameters will be determined. The investigators
      will explore if there is a difference between the course of sepsis markers of the two groups
      within 5 days after intervention in favor of the volatile group.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with septic shock are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time (4 hours) to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patients will not be informed about their group assignments, technicians, processing the samples, will not have any access to ICU or patient charts (= double blind trial)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of interleukin-6 over time</measure>
    <time_frame>5 days</time_frame>
    <description>To see if the interleukin-6 decreases under the influence of sevoflurane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pro-/anti-inflammatory mediators</measure>
    <time_frame>5 days</time_frame>
    <description>effect on inflammatory/anti- inflammatory mediators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor support</measure>
    <time_frame>5 days</time_frame>
    <description>Use of vasopressor support (norepinephrine, dobutamine, vasopressin) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure score (SOFA Score)</measure>
    <time_frame>5 days</time_frame>
    <description>Sepsis related organ failure score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Richmond Agitation Sedation Scale</measure>
    <time_frame>5 days</time_frame>
    <description>A scale to measure the agitation or sedation level of a patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Time of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Mortality information in intensive care unit and on the ward</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>Sevoflurane Sedation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized into experimental group will be treated with sevoflurane during 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol Sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized into Control Group will get continued intravenous sedation with propofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.</description>
    <arm_group_label>Sevoflurane Sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Included patients randomized in control group, intravenouse sedation is continued with propofol</description>
    <arm_group_label>Propofol Sedation</arm_group_label>
    <other_name>Propofol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients, age 18 to 80 years

          -  Intensive care Unit (ICU) patients with septic shock (despite fluid resuscitation
             vasopressors needed to maintain mean arterial pressure ≥65 millimeter of mercury
             (mmHg), and serum lactate &gt;2mmol/l even with fluid application)

          -  Treatment of septic shock on ICU with vasopressors not longer than 12 hours

          -  Sedation and mechanical ventilation on ICU

          -  Female patients of childbearing potential with negative pregnancy test

          -  Informed Consent as documented by signature

        Exclusion Criteria:

          -  Previous surgery and/or anesthesia (within last 7 days)

          -  Application of nitric oxide (NO)

          -  Suspected or known intolerance by history to volatile anesthetics (malignant
             hyperthermia)

          -  Immunosuppressive agents

          -  Systemic corticosteroids in the phase before hospitalization (&gt; 10mg/d prednisone)

          -  Significant concomitant disease (acute cerebral vascular event, acute coronary
             syndrome, decompensated heart failure, acute pulmonary edema, major cardiac
             arrhythmia, seizure, burn, chronic kidney disease, end stage liver failure,
             neuromuscular disease)

          -  AIDS

          -  Autoimmune disease

          -  Organ transplant

          -  Subject with active malignancy receiving

          -  chemotherapy or radiation treatment within last 60 days

          -  Hepatitis B/C virus infection

          -  Anti-tumor necrosis factor (TNF) therapy

          -  Pregnancy and/or Breast feeding

          -  Use of cytokine absorber

          -  Enrollment in any other clinical trial during the course of this trial, 30 days prior
             to its beginning or 30 days after its completion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schlaepfer, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Schlaepfer, PD</last_name>
    <phone>+41 44 255 4690</phone>
    <email>martin.schlaepfer@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schläpfer, PD</last_name>
    <phone>+41 44 255 4690</phone>
    <email>martin.schlaepfer@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonasspital Münsterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Neff, PD Dr. med.</last_name>
      <phone>071 686 2108</phone>
      <email>thomas.neff@sec.stgag.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin Schlaepfer, PD Dr med</last_name>
      <phone>+41442551111</phone>
      <email>martin.schlaepfer@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Beatrice Beck Schimmer, Prof Dr med</last_name>
      <email>beatrice.beck@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Marco Maggiorini, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Patricia Fodor, KD Dr. med.</last_name>
      <phone>+41444165202</phone>
      <email>patricia.fodor@triemli.zuerich.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waidspital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Giambarba, Dr. med.</last_name>
      <phone>+41443662021</phone>
      <email>christian.giambarba@waid.zuerich.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. The use of gene-expression profiling to identify candidate genes in human sepsis. Am J Respir Crit Care Med. 2007 Oct 1;176(7):676-84. Epub 2007 Jun 15.</citation>
    <PMID>17575094</PMID>
  </reference>
  <reference>
    <citation>Lu Y, Wang J, Yan J, Yang Y, Sun Y, Huang Y, Hu R, Zhang Y, Jiang H. Sevoflurane attenuate hypoxia-induced VEGF level in tongue squamous cell carcinoma cell by upregulating the DNA methylation states of the promoter region. Biomed Pharmacother. 2015 Apr;71:139-45. doi: 10.1016/j.biopha.2015.02.032. Epub 2015 Mar 3.</citation>
    <PMID>25960229</PMID>
  </reference>
  <reference>
    <citation>Klag T, Cantara G, Sechtem U, Athanasiadis A. Interleukin-6 Kinetics can be Useful for Early Treatment Monitoring of Severe Bacterial Sepsis and Septic Shock. Infect Dis Rep. 2016 Mar 21;8(1):6213. doi: 10.4081/idr.2016.6213. eCollection 2016 Mar 21.</citation>
    <PMID>27103972</PMID>
  </reference>
  <reference>
    <citation>Ríos-Toro JJ, Márquez-Coello M, García-Álvarez JM, Martín-Aspas A, Rivera-Fernández R, Sáez de Benito A, Girón-González JA. Soluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock. PLoS One. 2017 Apr 5;12(4):e0175254. doi: 10.1371/journal.pone.0175254. eCollection 2017.</citation>
    <PMID>28380034</PMID>
  </reference>
  <reference>
    <citation>Tschaikowsky K, Hedwig-Geissing M, Braun GG, Radespiel-Troeger M. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis. J Crit Care. 2011 Feb;26(1):54-64. doi: 10.1016/j.jcrc.2010.04.011. Epub 2010 Jun 19.</citation>
    <PMID>20646905</PMID>
  </reference>
  <reference>
    <citation>Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ; VANISH Investigators. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA. 2016 Aug 2;316(5):509-18. doi: 10.1001/jama.2016.10485.</citation>
    <PMID>27483065</PMID>
  </reference>
  <reference>
    <citation>Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K; International Forum of Acute Care Trialists. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72. doi: 10.1164/rccm.201504-0781OC.</citation>
    <PMID>26414292</PMID>
  </reference>
  <reference>
    <citation>Kellner P, Müller M, Piegeler T, Eugster P, Booy C, Schläpfer M, Beck-Schimmer B. Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury. Anesth Analg. 2017 Jan;124(1):194-203.</citation>
    <PMID>27782948</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Septic Shock</keyword>
  <keyword>Sevoflurane Conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

